|
|
|
|
Management of type IIb dyslipidemia
|
|
|
|
|
|
|
|
نویسنده
|
arai h. ,ishibashi s. ,bujo h. ,hayashi t. ,yokoyama s. ,oikawa s. ,kobayashi j. ,shirai k. ,ota t. ,yamashita s. ,gotoda t. ,harada-shiba m. ,sone h. ,eto m. ,suzuki h. ,yamada n.
|
|
منبع
|
journal of atherosclerosis and thrombosis - 2012 - دوره : 19 - شماره : 2 - صفحه:105 -114
|
|
چکیده
|
Although the japan atherosclerosis society guideline for the diagnosis and prevention of atherosclerosis cardiovascular diseases for the japanese population provides targets for low-density lipoprotein (ldl) cholesterol,triglycerides,and high-density lipoprotein (hdl) cholesterol to prevent cardiovascular disease in patients with dyslipidemia,there is no guideline specifically targeting the treatment of type iib dyslipidemia,which is one of the most common types of dyslipidemia,along with type iia and type iv dyslipidemia. type iib dyslipidemia is important because it sometimes accompanies atherogenic lipid profiles,such as small,dense ldl,remnants,low hdl cholesterolemia. it is also associated with type 2 diabetes mellitus,metabolic syndrome,and chronic kidney disease (ckd),and most patients with familial combined hyperlipidemia (fchl) show this phenotype; therefore,it is assumed that patients with type iib dyslipidemia have a high risk for cardiovascular disease. thus,the management of type iib dyslipidemia is very important for the prevention of cardiovascular disease,so we have attempted to provide a guideline for the management of type iib dyslipidemia.
|
|
کلیدواژه
|
Atherogenic dyslipidemia; Cardiovascular disease; Diabetes; Lifestyle modification; Metabolic syndrome
|
|
آدرس
|
department of human health sciences,kyoto university graduate school of medicine,kyoto, Japan, division of endocrinology and metabolism,diabetes center,department of medicine,jichi medical university graduate school of medicine,tochigi, Japan, department of genome research and clinical application,chiba university graduate school of medicine,chiba, Japan, department of geriatrics,nagoya university graduate school of medicine,nagoya, Japan, department of biochemistry,nagoya city university graduate school of medical sciences,nagoya, Japan, division of endocrinology and metabolism,department of medicine,nippon medical school,tokyo, Japan, department of lipidology,kanazawa university graduate school of medical science,kanazawa, Japan, internal medicine,sakura hospital,school of medicine,chiba, Japan, department of child health and welfare (pediatrics),faculty of medicine,university of the ryukyu,okinawa, Japan, department of cardiovascular medicine,osaka university graduate school of medicine,osaka, Japan, department of clinical and molecular epidemiology,22nd century medical and research center,university of tokyo hospital,tokyo, Japan, department of molecular innovation in lipidology,national cerebral and cardiovascular center research institute,osaka, Japan, department of internal medicine,university of tsukuba institute of clinical medicine,ibaraki, Japan, school of pharmaceutical sciences,ohu university and department of medicine,ohu university hospital,fukushima, Japan, department of endocrinology and metabolism,graduate school of comprehensive human sciences,university of tsukuba,ibaraki, Japan, university of tsukuba,ibaraki, Japan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|